ES2062514T3 - Sistema de procesamiento de levadura que comprende un aminoacido cargado negativamente adyacente al sitio de procesamiento. - Google Patents

Sistema de procesamiento de levadura que comprende un aminoacido cargado negativamente adyacente al sitio de procesamiento.

Info

Publication number
ES2062514T3
ES2062514T3 ES90904258T ES90904258T ES2062514T3 ES 2062514 T3 ES2062514 T3 ES 2062514T3 ES 90904258 T ES90904258 T ES 90904258T ES 90904258 T ES90904258 T ES 90904258T ES 2062514 T3 ES2062514 T3 ES 2062514T3
Authority
ES
Spain
Prior art keywords
amino acid
negatively charged
protein
system including
charged amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90904258T
Other languages
English (en)
Other versions
ES2062514T5 (es
Inventor
Soren Bjorn
Kjeld Norris
Fanny Norris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26065137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2062514(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DK494189A external-priority patent/DK494189D0/da
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of ES2062514T3 publication Critical patent/ES2062514T3/es
Application granted granted Critical
Publication of ES2062514T5 publication Critical patent/ES2062514T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Processing Of Solid Wastes (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Steroid Compounds (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Particle Accelerators (AREA)

Abstract

UN POLIPEPTIDO PARA LA PRODUCCION DE LEVADURA COMPRENDE LA FUSION DEL PEPTIDO DE SEÑAL, UN PEPTIDO LIDER Y UNA PROTEINA HETEROLOGUS O UN POLIPEPTIDO. EL POLIPEPTIDO ES MODIFICADO DE SU SECUENCIA AMINOACIDA EN UN LUGAR PROXIMO AL PROCESO, LOCALIZADO EN EL EXTREMO DE LA C-TERMINAL DEL PEPTIDO LIDER Y EN EL EXTREMO N-TERMINAL DE LA PROTEINA HETEROLOGUS, PARA SUMINISTRAR UNA PRESENTACION DEL LUGAR DE PROCESO QUE LO HACE ACCESIBLE A LA RUPTURA PEOTEOLITICA. DICHA PRESENTACION SE SUMINISTRA AÑADIENDO UNO O MAS AMINOACIDOS (AL MENOS UNO QUE ESTA CARGADO NEGATIVAMENTE) A CUALQUIER EXTREMO C-TERMINAL DEL LIDER O AL EXTREMO N-TERMINAL DE LA PROTEINA, O AMBOS. LA PROTEINA HETEROLOGUS PUEDE, POR SUPUESTO, SER UN PRECURSOR OPROTININ O INSULINA O UN ANALOGO DE ELLOS.
ES90904258T 1989-03-03 1990-03-01 Sistema de procesamiento de levadura que comprende un aminoacido cargado negativamente adyacente al sitio de procesamiento. Expired - Lifetime ES2062514T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK105489A DK105489D0 (da) 1989-03-03 1989-03-03 Polypeptid
DK494189A DK494189D0 (da) 1989-10-06 1989-10-06 Polypeptid

Publications (2)

Publication Number Publication Date
ES2062514T3 true ES2062514T3 (es) 1994-12-16
ES2062514T5 ES2062514T5 (es) 1998-06-01

Family

ID=26065137

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90904258T Expired - Lifetime ES2062514T5 (es) 1989-03-03 1990-03-01 Sistema de procesamiento de levadura que comprende un aminoacido cargado negativamente adyacente al sitio de procesamiento.

Country Status (23)

Country Link
US (3) US5395922A (es)
EP (1) EP0461165B2 (es)
JP (1) JP2609367B2 (es)
KR (1) KR970005928B1 (es)
AT (1) ATE110414T1 (es)
AU (1) AU624694B2 (es)
CA (1) CA2050336C (es)
CZ (1) CZ285239B6 (es)
DD (1) DD296965A5 (es)
DE (1) DE69011853T3 (es)
DK (2) DK105489D0 (es)
ES (1) ES2062514T5 (es)
FI (1) FI104985B (es)
HU (2) HU215538B (es)
IE (1) IE66469B1 (es)
IL (1) IL93609A (es)
NO (2) NO304236B1 (es)
NZ (1) NZ232742A (es)
PL (1) PL163532B1 (es)
RU (1) RU2194758C2 (es)
UA (1) UA27706C2 (es)
WO (1) WO1990010075A1 (es)
ZA (1) ZA901476B (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591603A (en) * 1987-08-28 1997-01-07 Novo Nordisk A/S Process for preparing aprotinin and aprotinin analogs in yeast cells
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
WO1990014431A1 (en) * 1989-05-19 1990-11-29 Biotechnology Research And Development Corporation Fusion proteins having an in vivo post-translational modification site and methods of manufacture and purification
GB9015825D0 (en) * 1990-07-18 1990-09-05 Ciba Geigy Ag In vitro processing of fusion proteins
DK300090D0 (da) * 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
GB9106185D0 (en) * 1991-03-22 1991-05-08 Wellcome Found Biological control agents
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FI92601C (fi) * 1992-03-11 1994-12-12 Marja Makarow Menetelmä hyötyproteiinien erittämiseksi hiivoista
US5521086A (en) * 1993-09-16 1996-05-28 Cephalon, Inc. Secretion sequence for the production of a heterologous protein in yeast
DE4417353A1 (de) * 1994-05-18 1996-01-25 Bayer Ag Verfahren zur Herstellung von rekombinantem Aprotinin und rekombinanten Aprotinin Varianten mit der natürlichen N-terminlaen Sequenz
IL114160A (en) * 1994-06-17 2006-12-31 Novo Nordisk As Dna constructs encoding heterologous proteins and processes for the heterologous protein production in yeast
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
US5861267A (en) * 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
ZA9610456B (en) * 1995-12-20 1997-06-20 Novo Nordisk As N-terminally extended proteins expressed in yeast
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
DE19629982A1 (de) 1996-07-25 1998-01-29 Bayer Ag Aprotinin-Varianten mit verbesserten Eigenschaften
EP1365028B1 (en) 1996-12-13 2009-03-18 Novartis Vaccines and Diagnostics, Inc. Method for expression of PDGF or IGF proteins in yeast
AU7873798A (en) * 1996-12-20 1998-07-17 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
EP0954589A1 (en) * 1997-01-24 1999-11-10 Novo Nordisk A/S Synthetic leader peptide sequences
US6046000A (en) * 1997-11-07 2000-04-04 Millennium Biotherapeutics, Inc. Method for identifying genes encoding signal sequences
KR20010034305A (ko) 1998-01-23 2001-04-25 한센 핀 베네드 효모에서 원하는 폴리펩티드를 만드는 방법
CN1415019A (zh) 1999-12-29 2003-04-30 诺沃挪第克公司 用于生产在酵母中具有改进发酵产量的胰岛素前体和胰岛素前体类似物的方法
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
CA2405557C (en) 2000-04-12 2013-09-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) * 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7595172B2 (en) 2001-07-24 2009-09-29 Novo Nordisk A/S Method for making acylated polypeptides
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
US7309505B2 (en) 2002-09-13 2007-12-18 Cornell Research Foundation, Inc. Using mutations to improve Aspergillus phytases
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
JP2007532096A (ja) 2003-11-14 2007-11-15 ノボ　ノルディスク　アクティーゼルスカブ アシル化されたインスリンの製造方法
CN102816228A (zh) 2003-12-03 2012-12-12 诺和诺德公司 单链胰岛素
WO2007020256A1 (en) 2005-08-16 2007-02-22 Novo Nordisk A/S Method for making mature insulin polypeptides
US8722620B2 (en) 2006-02-27 2014-05-13 Novo Nordisk A/S Insulin derivatives
US20080026376A1 (en) * 2006-07-11 2008-01-31 Huaming Wang KEX2 cleavage regions of recombinant fusion proteins
US8198046B2 (en) 2006-07-11 2012-06-12 Danisco Us Inc. KEX2 cleavage regions of recombinant fusion proteins
HUE029512T2 (en) 2006-09-22 2017-03-28 Novo Nordisk As Protease Resistant Insulin Analogs
JP5503968B2 (ja) 2006-09-27 2014-05-28 ノボ・ノルデイスク・エー／エス 成熟インスリンポリペプチドの作製方法
ES2425413T3 (es) 2006-11-22 2013-10-15 Novo Nordisk A/S Método para preparar carboxipeptidasa activada
JP5688969B2 (ja) 2007-07-16 2015-03-25 ノボ・ノルデイスク・エー／エス プロテアーゼに対して安定しているペグ化インスリンアナログ
ES2558930T3 (es) 2007-08-13 2016-02-09 Novo Nordisk A/S Análogos de la insulina de acción rápida
EP2178912B1 (en) 2007-08-15 2015-07-08 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
ES2526924T3 (es) 2007-08-15 2015-01-16 Novo Nordisk A/S Insulinas con una fracción acilo que comprende unidades repetitivas de aminoácidos que contienen alquilenglicol
US8501449B2 (en) 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
WO2009115469A1 (en) 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
WO2009121884A1 (en) 2008-04-01 2009-10-08 Novo Nordisk A/S Insulin albumin conjugates
CA2755300A1 (en) * 2009-03-12 2010-09-16 Bigtec Private Limited A polynucleotide and polypeptide sequence and methods thereof
PT2612677E (pt) 2009-06-26 2015-09-10 Novo Nordisk As Preparação compreendendo insulina, nicotinamida e arginina
CN102639559B (zh) 2009-11-25 2015-04-29 诺沃—诺迪斯克有限公司 用于制备多肽的方法
CN102791730A (zh) 2010-01-22 2012-11-21 诺沃—诺迪斯克有限公司 低度o-糖基化的fgf21的制备方法
WO2011161125A1 (en) 2010-06-23 2011-12-29 Novo Nordisk A/S Insulin derivatives containing additional disulfide bonds
CN102933599A (zh) 2010-06-23 2013-02-13 诺沃—诺迪斯克有限公司 包含额外的二硫键的人胰岛素
EP2585484A1 (en) 2010-06-23 2013-05-01 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
JP2014501239A (ja) 2010-12-14 2014-01-20 ノヴォ ノルディスク アー／エス インスリン、ニコチンアミドおよびアミノ酸を含む製剤
EP2651432A1 (en) 2010-12-14 2013-10-23 Novo Nordisk A/S Fast-acting insulin in combination with long-acting insulin
EP2720711A1 (en) 2011-06-15 2014-04-23 Novo Nordisk A/S Multi substituted insulins
RU2460795C1 (ru) * 2011-07-06 2012-09-10 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика") Способ микробиологического синтеза секретируемого соматотропина человека и штамм дрожжей saccharomyces cerevisiae - продуцент секретируемого соматотропина человека
WO2013186138A1 (en) 2012-06-14 2013-12-19 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and arginine
EP2925345B1 (en) 2012-12-03 2018-09-05 Merck Sharp & Dohme Corp. Method for making o-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
CN103254277B (zh) * 2013-05-03 2017-02-08 南京工业大学 强分泌性信号肽增强小肽模序及其应用
JP2016521701A (ja) 2013-06-07 2016-07-25 ノヴォ ノルディスク アー／エス 成熟インスリンポリペプチドを作製するための方法
PL233560B1 (pl) 2014-12-05 2019-10-31 Mabion Spolka Akcyjna Sposób otrzymywania insuliny lub analogu insuliny z prekursora rekombinowanego białka
US10562951B2 (en) 2015-03-10 2020-02-18 Merck Sharp & Dohme Corp. Process for preparing recombinant insulin using microfiltration
EP3303380B1 (en) 2015-06-02 2020-01-15 Novo Nordisk A/S Insulins with polar recombinant extensions
JP2018531901A (ja) 2015-08-25 2018-11-01 ノヴォ ノルディスク アー／エス 新規インスリン誘導体及びその医学的使用
WO2017032797A1 (en) 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
JP2018531900A (ja) 2015-08-25 2018-11-01 ノヴォ ノルディスク アー／エス 新規インスリン誘導体及びその医学的使用
KR102043067B1 (ko) * 2017-08-08 2019-11-11 엘지전자 주식회사 차량용 사이드 미러 및 차량
CN111032685A (zh) 2017-08-17 2020-04-17 诺沃挪第克公司 新型酰化胰岛素类似物及其用途
CA3159114A1 (en) 2019-12-11 2021-06-17 Frantisek Hubalek Novel insulin analogues and uses thereof
WO2023144240A1 (en) 2022-01-26 2023-08-03 Novo Nordisk Research Centre Oxford Limited Glucose sensitive insulin derivatives and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5712580A (en) * 1979-04-05 1980-10-09 James Joseph Connell Engine charging and scavenging
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
JPS60501140A (ja) * 1983-04-22 1985-07-25 アムジエン 酵母による外因性ポリペプチドの分泌
US4588684A (en) * 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
DK58285D0 (da) * 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
JPS61264000A (ja) * 1985-03-21 1986-11-21 イミユネツクス　コ−ポレイシヨン 標識ペプチドによるタンパク質の合成
JPS6236183A (ja) * 1985-06-20 1987-02-17 ザ・サルク・インステイチユ−ト・バイオテクノロジ−／インダストリアル・アソシエイツ・インコ−ポレ−テツド サツカロミセス・セレビシエからのポリペプチドの発現および分泌
MC1834A1 (fr) * 1986-07-10 1988-06-03 Transgene Sa Bloc fonctionnel d'adn et plasmide codant pour l'hirudine,levure transformee,procede de preparation de l'hirudine,hirudine obtenue et son utilisation
US4987070A (en) * 1987-03-04 1991-01-22 Suntory Limited Use of a 97 amino acid leader sequence from the E. coli B-galactosidase gene for the production of hanp and hptc as fusion proteins
AU1987088A (en) * 1987-06-24 1989-01-19 Novo Nordisk A/S A process for preparing a protein or polypeptide, a dna sequence coding for the polypeptide, a microorganism containing the dna sequence as well as the polypeptide and its use as a pharmaceutical preparation
DK450187D0 (da) * 1987-08-28 1987-08-28 Novo Industri As Fremgangsmaade til fremstilling af proteiner
DK463887D0 (da) * 1987-09-07 1987-09-07 Novo Industri As Gaerleader
JPH01240191A (ja) * 1988-02-16 1989-09-25 Green Cross Corp:The 酵母で機能する新規シグナルペプチドおよびこれを用いた異種蛋白質の分泌発現
DK336188D0 (da) * 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
EP0387319B1 (en) * 1988-07-23 1996-03-06 Delta Biotechnology Limited Secretory leader sequences
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid

Also Published As

Publication number Publication date
NO974899L (no) 1997-10-23
NO913427L (no) 1991-11-01
KR920701452A (ko) 1992-08-11
WO1990010075A1 (en) 1990-09-07
NZ232742A (en) 1991-10-25
AU5261290A (en) 1990-09-26
JPH04504846A (ja) 1992-08-27
HU215538B (hu) 1999-01-28
NO913427D0 (no) 1991-09-02
DE69011853T2 (de) 1994-12-15
HUT58370A (en) 1992-02-28
IE66469B1 (en) 1995-12-27
PL163532B1 (pl) 1994-04-29
EP0461165B2 (en) 1998-03-25
DK0461165T3 (da) 1994-11-21
AU624694B2 (en) 1992-06-18
DK105489D0 (da) 1989-03-03
FI104985B (fi) 2000-05-15
CZ285239B6 (cs) 1999-06-16
DE69011853D1 (de) 1994-09-29
HU211600A9 (en) 1995-12-28
ATE110414T1 (de) 1994-09-15
IE900749L (en) 1990-09-03
NO304236B1 (no) 1998-11-16
CZ103990A3 (cs) 1999-03-17
CA2050336C (en) 2000-01-18
ZA901476B (en) 1990-11-28
EP0461165B1 (en) 1994-08-24
ES2062514T5 (es) 1998-06-01
IL93609A (en) 2001-11-25
FI914125A0 (fi) 1991-09-02
DD296965A5 (de) 1991-12-19
HU902376D0 (en) 1991-11-28
US5395922A (en) 1995-03-07
CA2050336A1 (en) 1990-09-04
JP2609367B2 (ja) 1997-05-14
US5514585A (en) 1996-05-07
US5510249A (en) 1996-04-23
KR970005928B1 (ko) 1997-04-22
NO974899D0 (no) 1997-10-23
EP0461165A1 (en) 1991-12-18
UA27706C2 (uk) 2000-10-16
DE69011853T3 (de) 1998-06-25
IL93609A0 (en) 1990-12-23
RU2194758C2 (ru) 2002-12-20

Similar Documents

Publication Publication Date Title
ES2062514T5 (es) Sistema de procesamiento de levadura que comprende un aminoacido cargado negativamente adyacente al sitio de procesamiento.
ES2059547T3 (es) Expresion y secrecion mejoradas de proteinas heterologas en levadura, empleando secuencia conductora de factor alfa truncado.
ES2124295T3 (es) Expresion y purificacion de factor tisular soluble recombinante.
ES2124685T3 (es) Variantes del inhibidor de la tripsina pancreatica bovina, su produccion y uso.
PT99118A (pt) Processo de preparacao de protease de interleucina 1b,de inibidores da protease de interleucina 1b e de composicoes farmaceuticas
ATE139540T1 (de) Heilmittelpeptide
DK521386A (da) Fremgangsmaade til bestemmelse af aminosyre-sekvensen af et polypeptid, som er komplementaert til et peptid eller protein eller en del heraf, samt middel til brug ved fremgangsmaaden
MX9306220A (es) Ptp 1d: una proteina tirosina fosfatasa novedosa.
ES2065907T3 (es) Procedimiento para la produccion de un peptido fisiologicamente activo que contiene un resto cisteina.
Gluschankof et al. The somatostatin-28 convertase of rat brain cortex generates both somatostatin-14 and somatostatin-28 (1–12)
PT95016A (pt) Processo para a preparacao de peptidos terapeuticos
PT98332A (pt) Metodo para a producao de uma proteina biologicamente activa por processamento in vitro de proteinas de fusao
Anouar et al. Identification of a novel secretogranin II-derived peptide in the adult and fetal human adrenal gland
ATE46173T1 (de) Pharmakologisch aktive peptide.
EP0305063A3 (en) A process for production of c-terminal alpha-amide peptides
ATE92078T1 (de) Pharmakologisch aktive peptide.
AR247473A1 (es) Una composicion que produce una respuesta lactogenica o crecimiento en ganado bovino, excluidas todas sus aplicaciones terapeuticas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 461165

Country of ref document: ES